SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting30-05-2023
30-05-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to 'Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis', which we shall be releasing after sending this letter to you. This submission is being made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.30-05-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to 'Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY(tm) in Europe, Australia and New Zealand', which we shall be releasing after sending this letter to you. This submission is being made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.30-05-2023
Sun Pharma: Stretched valuation a sticking point, what else to watch out for?
Elevated promotional/travel expenses and increased competitive intensity would weigh on margins29-05-2023
Sun Pharmaceutical Industries Results Earnings Call for Q4FY23
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.27-05-2023
Sun Pharma share price: Key triggers for future performance in this pharma stock after Q4 results; should you buy?
Sun Pharma shares will be in focus on Monday after its Q4 earnings. Although Sun Pharma's fourth-quarter earnings were a mixed bag, analysts are still optimistic about this pharma player and have recommended buying on the stock price.27-05-2023
Sun Pharma proposes to fully acquire Israel-based Taro Pharmaceutical Industries
Under the indicative proposal, post the acquisition, Taro will become a wholly-owned subsidiary of Sun Pharma and will be delisted from NYSE.27-05-2023
Sun Pharma proposes to acquire Israel-based Taro Pharmaceutical Industries
Sun Pharmaceutical Industries on Saturday said it has proposed to fully acquire Israel-based Taro Pharmaceutical Industries through a reverse triangular merger. The Mumbai-based drug major said it has issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares for a purchase price of USD 38 per ordinary share in cash. Sun Pharma currently owns a 78.48 per cent stake in Taro. "We envisage the proposed transaction to be consummated in the form of a reverse triangular merger under the Israeli Companies Law, 1999 and practice," Sun Pharma said in a regulatory filing. The purchase price represents a premium of 31.2 per cent over Taro's closing price on May 25, 2023, a 41.5 per cent premium over Taro's average closing price in the last 60 days and a compelling liquidity opportunity for Taro's shareholders, it added. Under the indicative proposal, post the acquisition, Taro will become a wholly-owned27-05-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting27-05-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Non-Binding Indication Of Interest To Acquire Shares Of Taro Pharmaceutical Industries Ltd., Israel
On May 26, 2023, Sun Pharmaceutical Industries Limited ('Company') has issued a letter to the Board of Directors of Taro Pharmaceutical Industries Ltd., Israel ('Taro') with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares in Taro, other than any shares already held by the Company or its affiliates (For a purchase price of $38 per ordinary share, in cash the 'Proposal'). Copy of the letter containing the Proposal is enclosed herewith as Annexure A. This disclosure is being submitted pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.27-05-2023